Lipoprotein lipase deficiency (LPLD) results from mutations within the lipoprotein lipase (LPL) gene that lead to a complete lack of catalytically active LPL protein. Glybera was one of the first adeno-associated virus (AAV) gene replacement therapy to receive European Medicines Agency regulatory approval for the treatment of LPLD. However, Glybera is no longer marketed potentially due to a combination of economical, manufacturing, and vector-related issues. The aim of this study was to develop a more efficacious AAV gene therapy vector for LPLD. Following preclinical biodistribution, efficacy and non-Good Laboratory Practice toxicity studies with novel AAV1 and AAV8-based vectors in mice, we identified AAV8 pVR59. AAV8 pVR59 delivered a codon-optimized, human gain-of-function hLPLS447X transgene driven by a CAG promoter in an AAV8 capsid. AAV8 pVR59 was significantly more efficacious, at 10- to 100-fold lower doses, compared with an AAV1 vector based on Glybera, when delivered intramuscularly or intravenously, respectively, in mice with LPLD. Efficient gene transfer was observed within the injected skeletal muscle and liver following delivery of AAV8 pVR59, with long-term correction of LPLD phenotypes, including normalization of plasma triglycerides and lipid tolerance, for up to 6 months post-treatment. While intramuscular delivery of AAV8 pVR59 was well tolerated, intravenous administration augmented liver pathology. These results highlight the feasibility of developing a superior AAV vector for the treatment of LPLD and provide critical insight for initiating studies in larger animal models. The identification of an AAV gene therapy vector that is more efficacious at lower doses, when paired with recent advances in production and manufacturing technologies, will ultimately translate to increased safety and accessibility for patients.
Get full access to this article
View all access options for this article.
References
1.
WangH, EckelRH. Lipoprotein lipase: From gene to obesity. Am J Physiol Endocrinol Metab, 2009; 297(2):271–288; doi: 10.1152/ajpendo.90920.2008
2.
OlivecronaG. Role of lipoprotein lipase in lipid metabolism. Curr Opin Lipidol, 2016; 27(3):233–241; doi: 10.1097/MOL.0000000000000297
GoldbergIJ. Lipoprotein lipase and lipolysis: Central roles in lipoprotein metabolism and atherogenesis. J Lipid Res, 1996; 37(4):693–707; doi: 10.1016/s0022-2275(20)37569-6
ClarkeBA, DrujanD, WillisMS, et al.The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab, 2007; 6(5):376–385; doi: 10.1016/j.cmet.2007.09.009
10.
RipJ, NiermanMC, RossCJ, et al.Lipoprotein lipase S447X: A naturally occurring gain-of-function mutation. Arterioscler Thromb Vasc Biol, 2006; 26(6):1236–1245; doi: 10.1161/01.ATV.0000219283.10832.43
11.
RossCJD, TwiskJ, MeulenbergJM, et al.Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPLS447X beneficial mutation. Hum Gene Ther, 2004; 15(9):906–919; doi: 10.1089/hum.2004.15.906
12.
RossCJD, TwiskJ, BakkerAC, et al.Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation. Hum Gene Ther, 2006; 17(5):487–499; doi: 10.1089/hum.2006.17.487
13.
CarpentierAC, FrischF, LabbeSM, et al.Effect of alipogene tiparvovec (aav1-lpls447x) on postprandial chylomicron metabolism in Lipoprotein lipase-deficient patients. J Clin Endocrinol Metab, 2012; 97(5):1635–1644; doi: 10.1210/jc.2011-3002
14.
GaudetD, MéthotJ, DéryS, et al.Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPL S447X) gene therapy for lipoprotein lipase deficiency: An open-label trial. Gene Ther, 2013; 20(4):361–369; doi: 10.1038/gt.2012.43
15.
GaudetD, StroesES, MéthotJ, et al.Long-term retrospective analysis of gene therapy with Alipogene Tiparvovec and its effect on lipoprotein lipase deficiency-induced pancreatitis. Hum Gene Ther, 2016; 27(11):916–925; doi: 10.1089/hum.2015.158
16.
StroesES, NiermanMC, MeulenbergJJ, et al.Intramuscular administration of AAV1-lipoprotein lipaseS447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol, 2008; 28(12):2303–2304; doi: 10.1161/ATVBAHA.108.175620
KassnerU, HollsteinT, GrenkowitzT, et al.Gene therapy in lipoprotein lipase deficiency: Case report on the first patient treated with alipogene tiparvovec under daily practice conditions. Hum Gene Ther, 2018; 29(4):520–527; doi: 10.1089/hum.2018.007
19.
HitoshiN, Ken-ichiY, Jun-ichiM. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene, 1991; 108(2):193–199; doi: 10.1016/0378-1119(91)90434-D
20.
BlainM, ZengY, BendjelloulM, et al.Strong muscle-specific regulatory cassettes based on multiple copies of the human slow troponin I gene upstream enhancer. Hum Gene Ther, 2010; 21(1):127–134; doi: 10.1089/hum.2008.208
21.
GilbertR, GuilbaultC, GagnonD, et al.Establishment and validation of new complementing cells for production of E1-deleted adenovirus vectors in serum-free suspension culture. J Virol Methods, 2014; 208:177–188; doi: 10.1016/j.jviromet.2014.08.013
22.
BourbeauD, LauCJ, JaimeJ, et al.Improvement of antitumor activity by gene amplification with a replicating but nondisseminating adenovirus. Cancer Res, 2007; 67(7):3387–3395; doi: 10.1158/0008-5472.CAN-06-4317
23.
ElahiSM, Nazemi-MoghaddamN, GadouryC, et al.A rapid Focus-Forming Assay for quantification of infectious adenoviral vectors. J Virol Methods, 2021; 297:114267; doi: 10.1016/j.jviromet.2021.114267
24.
RossCJD, LiuG, KuivenhovenJA, et al.Complete rescue of lipoprotein lipase-deficient mice by somatic gene transfer of the naturally occurring LPLS447X beneficial mutation. Arterioscler Thromb Vasc Biol, 2005; 25(10):2143–2150; doi: 10.1161/01.ATV.0000176971.27302.b0
25.
RobertMA, NassouryN, ChahalPS, et al.Gene Transfer of ZMapp antibodies mediated by recombinant adeno-associated virus protects against ebola infections. Hum Gene Ther, 2018; 29(4):452–466; doi: 10.1089/hum.2017.101
26.
CôtéJ, GarnierA, MassieB, et al.Serum-free production of recombinant proteins and adenoviral vectors by 293SF-3F6 cells. Biotechnol Bioeng, 1998; 59(5):567–575; doi: 10.1002/(SICI)1097-0290(19980905)59:5<567::AID-BIT6>3.0.CO;2-8
27.
ChahalPS, SchulzeE, TranR, et al.Production of adeno-associated virus (AAV) serotypes by transient transfection of HEK293 cell suspension cultures for gene delivery. J Virol Methods, 2014; 196:163–173; doi: 10.1016/j.jviromet.2013.10.038
28.
ChahalPS, AucoinMG, KamenA. Primary recovery and chromatographic purification of adeno-associated virus type 2 produced by baculovirus/insect cell system. J Virol Methods, 2007; 139(1):61–70; doi: 10.1016/j.jviromet.2006.09.011
29.
ZolotukhinS, ByrneBJ, MasonE, et al.Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther, 1999; 6(6):973–985; doi: 10.1038/sj.gt.3300938
30.
ColemanT, SeipRL, GimbleJM, et al.COOH-terminal disruption of lipoprotein lipase in mice is lethal in homozygotes, but heterozygotes have elevated triglycerides and impaired enzyme activity. J Biol Chem, 1995; 270(21):12518–12525; doi: 10.1074/jbc.270.21.12518
31.
WeinstockPH, BisgaierCL, Aalto-SetalaK, et al.Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes. J Clin Invest, 1995; 96(6):2555–2568; doi: 10.1172/JCI118319
32.
BasuD, ManjurJ, JinW. Determination of lipoprotein lipase activity using a novel fluorescent lipase assay. J Lipid Res, 2011; 52(4):826–832; doi: 10.1194/jlr.D010744
33.
LaffertyMJ, BradfordKC, ErieDA, et al.Angiopoietin-like protein 4 inhibition of lipoprotein lipase: Evidence for reversible complex formation. J Biol Chem, 2013; 288(40):28524–28534; doi: 10.1074/jbc.M113.497602
34.
MartinoAT, HerzogRW, AnegonI, et al.Measuring immune responses to recombinant AAV gene transfer. Methods Mol Biol, 2011; 807:259; doi: 10.1007/978-1-61779-370-7_11
35.
HayneCK, LaffertyMJ, EglingerBJ, et al.Biochemical analysis of the lipoprotein lipase truncation variant, LPLS447X, reveals increased lipoprotein uptake. Biochemistry, 2017; 56(3):525–533; doi: 10.1021/acs.biochem.6b00945
36.
CleeSM, LoubserO, CollinsJ, et al.The LPL S447X cSNP is associated with decreased blood pressure and plasma triglycerides, and reduced risk of coronary artery disease. Clin Genet, 2001; 60(4):293–300; doi: 10.1034/j.1399-0004.2001.600407.x
37.
WittrupHH, NordestgaardBG, SteffensenR, et al.Effect of gender on phenotypic expression of the S447X mutation in LPL: The Copenhagen City Heart Study. Atherosclerosis, 2002; 165(1):119–126; doi: 10.1016/S0021-9150(02)00183-1
38.
NguyenGN, EverettJK, KafleS, et al.A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells. Nat Biotechnol, 2021; 39(1):47–55; doi: 10.1038/s41587-020-0741-7
39.
MackDL, PoulardK, GoddardMA, et al.Systemic AAV8-mediated gene therapy drives whole-body correction of myotubular myopathy in dogs. Mol Ther, 2017; 25(4):839–854; doi: 10.1016/j.ymthe.2017.02.004
40.
NathwaniAC, ReissUM, TuddenhamEGD, et al.Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med, 2014; 371(21):1994–2004.
41.
GreigJA, PengH, OhlsteinJ, et al.Intramuscular injection of AAV8 in mice and macaques is associated with substantial hepatic targeting and transgene expression. PLoS One, 2014; 9(11):1–11; doi: 10.1371/journal.pone.0112268
42.
MuraineL, BensalahM, DhiabJ, et al.Transduction efficiency of adeno-associated virus serotypes after local injection in mouse and human skeletal muscle. Hum Gene Ther, 2020; 31(3–4):233–240; doi: 10.1089/hum.2019.173
43.
ZincarelliC, SoltysS, RengoG, et al.Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. Mol Ther, 2008; 16(6):1073–1080; doi: 10.1038/mt.2008.76
44.
WesthausA, Cabanes CreusM, DilworthKL, et al.Assessment of pre-clinical liver models based on their ability to predict the liver-tropism of AAV vectors. Hum Gene Ther, 2023; 34(7–8):273–288; doi: 10.1089/hum.2022.188
45.
DavidoffAM, GrayJT, NgCYC, et al.Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol Ther, 2005; 11(6):875–888; doi: 10.1016/j.ymthe.2004.12.022
46.
NathwaniAC, GrayJT, NgCYC, et al.Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood, 2006; 107(7):2653–2661; doi: 10.1182/blood-2005-10-4035
47.
PeiX, HeT, HallNE, et al.AAV8 virions hijack serum proteins to increase hepatocyte binding for transduction enhancement. Virology, 2018; 518:95–102; doi: 10.1016/j.virol.2018.02.007
48.
NietupskiJB, HurlbutGD, ZieglerRJ, et al.Systemic administration of AAV8-α-galactosidase a induces humoral tolerance in nonhuman primates despite low hepatic expression. Mol Ther, 2011; 19(11):1999–2011; doi: 10.1038/mt.2011.119
49.
BasuD, GoldbergIJ. Regulation of lipoprotein lipase-mediated lipolysis of triglycerides. Curr Opin Lipidol, 2020; 31(3):154–160; doi: 10.1097/MOL.0000000000000676
50.
Ashbourne ExcoffonKJD, LiuG, MiaoL, et al.Correction of hypertriglyceridemia and impaired fat tolerance in lipoprotein lipase—Deficient mice by adenovirus-mediated expression of human lipoprotein lipase. Arterioscler Thromb Vasc Biol, 1997; 17(11):2532–2539; doi: 10.1161/01.atv.17.11.2532
51.
ShimizuK, NishimutaS, FukumuraY, et al.Liver-specific overexpression of lipoprotein lipase improves glucose metabolism in high-fat diet-fed mice. PLoS One, 2022; 17(9):e0274297; doi: 10.1371/journal.pone.0274297
52.
FanJ, UnokiH, KojimaN, et al.Overexpression of lipoprotein lipase in transgenic rabbits inhibits diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem, 2001; 276(43):40071–40079; doi: 10.1074/jbc.M105456200
53.
HidalgoNJ, PandoE, AlbertiP, et al.Elevated serum triglyceride levels in acute pancreatitis: A parameter to be measured and considered early. World J Surg, 2022; 46(7):1758–1767; doi: 10.1007/s00268-022-06533-w
54.
BanksPA, FreemanML, FassR, et al.Practice guidelines in acute pancreatitis. Am J Gastroenterol, 2006; 101(10):2379–2400; doi: 10.1111/j.1572-0241.2006.00856.x
55.
PedersenSB, LangstedA, NordestgaardBG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med, 2016; 176(12):1834–1842; doi: 10.1001/JAMAINTERNMED.2016.6875
56.
BiswasM, KumarSRP, TerhorstC, et al.Gene therapy with regulatory T cells: A beneficial alliance. Front Immunol, 2018; 9:1; doi: 10.3389/fimmu.2018.00554
57.
PoupiotJ, Costa VerderaH, HardetR, et al.Role of regulatory T cell and effector T cell exhaustion in liver-mediated transgene tolerance in muscle. Mol Ther Methods Clin Dev, 2019; 15:83–100; doi: 10.1016/j.omtm.2019.08.012
58.
KumarSRP, HoffmanBE, TerhorstC, et al.The balance between CD8+ T cell-mediated clearance of AAV-encoded antigen in the liver and tolerance is dependent on the vector dose. Mol Ther, 2017; 25(4):880–891; doi: 10.1016/j.ymthe.2017.02.014
59.
KishimotoTK, SamulskiRJ. Addressing high dose AAV toxicity–“one and done” or “slower and lower”?. Expert Opin Biol Ther, 2022; 22(9):1067–1071; doi: 10.1080/14712598.2022.2060737
60.
VerderaHC, KurandaK, MingozziF. AAV vector immunogenicity in humans: A long journey to successful gene transfer. Mol Ther, 2020; 28(3):723–746; doi: 10.1016/j.ymthe.2019.12.010
61.
RipJ, NiermanMC, SiertsJA, et al.Gene therapy for lipoprotein lipase deficiency: Working toward clinical application. Hum Gene Ther, 2005; 16(11):1276–1286; doi: 10.1089/hum.2005.16.1276
62.
BishopJR, Passos-BuenoMR, FongL, et al.Deletion of the basement membrane heparan sulfate proteoglycan type XVIII collagen causes hypertriglyceridemia in mice and humans. PLoS One, 2010; 5(11):e13919; doi: 10.1371/journal.pone.0013919
63.
Levak-FrankS, RadnerH, WalshA, et al.Muscle-specific overexpression of lipoprotein lipase causes a severe myopathy characterized by proliferation of mitochondria and peroxisomes in transgenic mice. J Clin Invest, 1995; 96(2):976–986; doi: 10.1172/JCI118145
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
